5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms.

5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms. Abstract Text:

Daniela Velati,Michele Viana,Stefania Cresta,Paola Mantegazza,Lucia Testa,Diego Bettucci,Maurizio Rinaldi,Grazia Sances,Cristina Tassorelli,Giuseppe Nappi,Pier Luigi Canonico,Emilia Martignoni,Armando A Genazzani,

Triptans mediate vasoconstriction of meningeal vessels via stimulation of vascular 5-hydroxytryptamine (5-HT)(1B) receptors. These drugs are recommended for acute treatment in patients with moderate-to-severe migraine attacks and in those patients with mild-to-moderate headache that are not controlled adequately by other agents. Yet, approximately 25% of all migraine users and 40% of all attacks do not respond to triptan treatment. Among the hypothesis to explain this is the possibility that genetic single nucleotide polymorphisms that alter the receptor, for example changing the transcriptional rate and therefore the amount of target protein might change the clinical response to these drugs. In the present contribution, we therefore decided to evaluate whether single nucleotide polymorphisms on the 5-HT(1B) gene might contribute to inter-individual variability in clinical responses to triptans. Two polymorphisms in the promoter region of the 5-HT(1B) receptor (T-261G and A-161T) and the synonymous variation G861C in the coding region were genotyped by restriction fragment length polymorphism in 105 migraine patients. In our sample population, 71% of patients responded to triptans. Allelic and diplotype frequencies were not significantly different between responders and non-responders. On the other hand, extrapolation of in vitro data on promoter activity would suggest that patients with higher copy number of receptors respond slightly better. Our data therefore do not support the involvement of 5-HT(1B) single nucleotide polymorphisms in mediating the inter-individual variability to triptans.

5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms. Publishing Authors By Initials

D Velati,M Viana,S Cresta,P Mantegazza,L Testa,D Bettucci,M Rinaldi,G Sances,C Tassorelli,G Nappi,PL Canonico,E Martignoni,AA Genazzani,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of pharmacology

VOLUME: 580

Page Numbers: 43-7

Journal Abbreviation: Eur. J. Pharmacol.

ISSN: 0014-2999

DAY: 30

MONTH: 10

YEAR: 2007

5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 1254354

5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: 5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for 5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms.

AFFILIATION: DiSCAFF and DFB Center, Via Bovio, 6, 28100 Novara, Italy.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms Related Publications

• 5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms.
• A case of acro-cephalo-syndactylia [Hebrew text].
• Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
• Brain derived neurotrophic factor circulating levels in patients undergoing IVF.
• Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature.
• CSF beta-EP in headache and depression.
• Calcineurin primes immature gonadotropin-releasing hormone-secreting neuroendocrine cells for migration.
• Characterization of NAD Uptake in Mammalian Cells.
• Circadian variations of proopiocortin-related peptides in children with migraine.
• Click chemistry reactions in medicinal chemistry: Applications of the 1,3-dipolar cycloaddition between azides and alkynes.
• Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: The brain and the vessels.
• Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions.
• Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
• Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances.
• Endorphin patterns within the headache spectrum disorders.
• Evaluation of central opioid tonus in menstrual migraine.
• Functional hypothalamic amenorrhea: Current view on neuroendocrine aberrations.
• Involvement of serotonin in the central control of opioid secretion.
• Naloxone test in primary headache sufferers.
• Neuroendocrine effects of flunarizine treatment in postmenopausal women.
• Opioid control of the hypothalamus-pituitary-adrenal axis cyclically fails in menstrual migraine.
• P26.08: Bilateral hemorrhagic fetal ovarian cyst: a case report.
• P26.12: Prenatal sonographic features of chloride diarrhea.
• Primary headaches: reduced circulating beta-lipotropin and beta-endorphin levels with impaired reactivity to acupuncture.
• Reduced testosterone levels in cluster headache: a stress-related phenomenon?
• Sympathergic/neuroendocrine reactivity as a marker of adaptive processes underlying migraine susceptibility.
• The association of menstrual migraine with the premenstrual syndrome.
• The management of patients with uterine sarcoma: A debated clinical challenge.
• The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature.
• Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.